Evaluation of LPS-Induced Acute Lung Injury Attenuation in Rats by Aminothiazole-Paeonol Derivatives
作者:Pin-Kuei Fu、Chi-Yu Yang、Su-Chin Huang、Yu-Wen Hung、Kee-Ching Jeng、Ying-Pei Huang、Hong Chuang、Nai-Chun Huang、Jui-Ping Li、Ming-Hua Hsu、Jen-Kun Chen
DOI:10.3390/molecules22101605
日期:——
Paeonol is a key phenolic compound in the root bark of Moutan Cortex Radicis that has been used in traditional Chinese Medicine to ameliorate inflammation. A series of aminothiazole-paeonol derivatives (APDs) were synthesized in this work and subjected to preliminary evaluation in cells followed by verification in animals. Quantification of monocyte chemotactic protein-1 (MCP-1) and interleukin-6 (IL-6) in culture media of LPS-activated A549 cells, a lung epithelial adenocarcinoma cell line, were used to investigate the anti-inflammatory capability of APDs. ALI-bearing rats were employed to verify therapeutic efficacy of APDs according to observations of total cells, protein amounts, MCP-1 and IL-6 in bronchoalveolar lavage fluid (BALF). Histopathological examinations of lung tissues were consequently applied for validation of APDs. Among these compounds, 2-(2-aminothiazol-4-yl)-5-methoxyphenol (4) had the most potent activity, showing comparable inhibition of MCP-1/IL-6 and superior elimination of neutrophil infiltration and protein exudation in lungs compared to others as well as dexamethasone. This study demonstrated a comprehensive strategy to evaluate APDs through integration of cell-based screening and animal-based verification. In order to fulfill unmet needs of treating acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), APDs introduced in this work could be promising lead compounds to develop high potent anti-inflammation agents.
芍药苷是牡丹树皮中一种关键的酚类化合物,传统中医用其改善炎症。在这项研究中,合成了一系列氨基噻唑-芍药苷衍生物(APDs),并进行了细胞初步评估,随后在动物中进行了验证。通过量化LPS激活的A549细胞(肺上皮腺癌细胞系)培养基中的单核细胞趋化蛋白-1(MCP-1)和白细胞介素-6(IL-6),以研究APDs的抗炎能力。针对急性肺损伤(ALI)模型大鼠的实验,通过观察支气管肺泡灌洗液(BALF)中的细胞总数、蛋白质含量、MCP-1和IL-6来验证APDs的治疗效果。随后对肺组织进行了组织病理学检查以验证APDs的效果。在这些化合物中,2-(2-氨基噻唑-4-基)-5-美氧基苯酚(4)的活性最强,与其他化合物及地塞米松相比,显示出对MCP-1/IL-6的抑制作用相当及对中性粒细胞浸润和肺部蛋白渗出物的优越清除效果。本研究通过细胞基础筛选与动物基础验证的结合,展示了评估APDs的综合策略。为了满足治疗急性肺损伤(ALI)和急性呼吸窘迫综合症(ARDS)的未满足需求,本研究引入的APDs可能成为开发高效抗炎药物的有前景的先导化合物。